Impact of Omalizumab on Patient Reported Outcomes in Chronic Idiopathic Urticaria: Results From XTEND-CIU, a 48-Week, Randomized, Placebo-Controlled Study
Journal of Allergy and Clinical Immunology - United States
doi 10.1016/j.jaci.2017.12.955
Full Text
Open PDFAbstract
Available in full text
Date
February 1, 2018
Authors
Publisher
Elsevier BV